916 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 916 shares of the company’s stock, valued at approximately $29,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of LENZ. SG Americas Securities LLC grew its stake in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after acquiring an additional 935 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in LENZ Therapeutics in the 4th quarter valued at $168,000. MetLife Investment Management LLC acquired a new stake in LENZ Therapeutics in the 3rd quarter valued at $182,000. GSA Capital Partners LLP acquired a new stake in LENZ Therapeutics in the 3rd quarter valued at $246,000. Finally, Jane Street Group LLC acquired a new stake in LENZ Therapeutics in the 3rd quarter valued at $286,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Trading Down 0.2 %

Shares of NASDAQ LENZ opened at $25.22 on Friday. LENZ Therapeutics, Inc. has a twelve month low of $14.42 and a twelve month high of $38.93. The stock has a 50 day moving average of $27.31 and a two-hundred day moving average of $26.95.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, LENZ Therapeutics currently has an average rating of “Buy” and a consensus target price of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.